Novarad’s augmented reality solution gains FDA clearance

Novarad’s OpenSight Augmented Reality (AR) System is the first AR solution for Microsoft HoloLens to receive FDA clearance for pre-operative surgical planning, the company announced this week. OpenSight overlays 2D, 3D and 4D images over the patient’s body, helping them plan surgeries in advance.  

“This is transformative technology that will unite preoperative imaging with augmented reality to improve the precision, speed and safety of medical procedures,” Wendell Gibby, MD, Novarad CEO and co-creator of OpenSight, said in a prepared statement. “This internal visualization can now be achieved without the surgeon ever making an incision, improving outcomes in a world of more precise medicine.”

The technology allows providers to highlight certain parts of the body, position guidance systems ahead of the surgery and more. Medical students can also use the solution so train as they perform AR dissections on cadavers.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The ACR hopes these changes, including the addition of diagnostic performance feedback, will help reduce the number of patients with incidental nodules lost to follow-up each year.

And it can do so with almost 100% accuracy as a first reader, according to a new large-scale analysis.

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.